Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

Daniele Di Marzio
2008 Vascular Health and Risk Management  
Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefi t cardiovascular parameters, such as lipids, blood pressure, infl ammatory biomarkers, endothelial function and fi brinolytic state. In this review, we summarise the
more » ... ummarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions.
doi:10.2147/vhrm.s993 fatcat:z2nty4akcbep5gqvb3762cg7py